Document is current
Any future updates will be listed below
-
Authors
Cassotta, Antonino https://orcid.org/0000-0001-8674-4294
Mikol, Vincent
Bertrand, Thomas https://orcid.org/0000-0002-9188-6673
Pouzieux, Stéphanie
Le Parc, Josiane
Ferrari, Paul
Dumas, Jacques
Auer, Michael
Deisenhammer, Florian
Gastaldi, Matteo
Franciotta, Diego
Silacci-Fregni, Chiara
Fernandez Rodriguez, Blanca
Giacchetto-Sasselli, Isabella
Foglierini, Mathilde https://orcid.org/0000-0001-7538-4262
Jarrossay, David
Geiger, Roger https://orcid.org/0000-0002-8016-1669
Sallusto, Federica https://orcid.org/0000-0003-3750-2752
Lanzavecchia, Antonio
Piccoli, Luca https://orcid.org/0000-0002-1085-6502
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (115303, 115303, 115303)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (176165)
- License Information
-
More Information
Article History
Received: 18 April 2019
Accepted: 29 July 2019
First Online: 9 September 2019
Competing interests
: V.M., T.B., S.P., J.L.P., P.F. and J.D. are all employees of Sanofi. F.D. has participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Biogen Idec, Celgene, Genzyme-Sanofi, Merck, Novartis Pharma, and Roche. His institution has received research grants from Biogen and Genzyme Sanofi. He is section editor of the MSARD Journal (Multiple Sclerosis and Related Disorders). A.L. is a Senior Vice President and Senior Research Fellow at Vir Biotechnology, Inc.
